Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003

British Journal of Cancer

Volumn 96, Issue 11, 2007, Pages 1767-1771

  Van Blankenstein, M ^a,c   Looman, C W N ^a   Siersema, P D ^a   Kuipers, E J ^a   Coebergh, J W W ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b The Netherlands   (Netherlands)

^c NONE   (Netherlands)

Author keywords

Adenocarcinoma of the cardia; Adenocarcinoma of the oesophagus; Age period cohort pattern analysis; Barrett's oesophagus; Epidemiological trends

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CARDIA CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX RATIO; SMOKING; TREND STUDY;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIA; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; FORECASTING; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NETHERLANDS; REGRESSION ANALYSIS; STOMACH NEOPLASMS; TIME FACTORS;

EID: 34249828670     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603798     Document Type: Article

References (44)

1. Bardou M, Barkun AN, Ghosn J, Hudson M, Rahme E (2004) Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol 2: 880-887
2. Barendregt JJ, Looman CW, Bronnum-Hansen H (2002) Comparison of cohort smoking intensities in Denmark and the Netherlands. Bull World Health Organ 80: 26-32
3. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH (2001) Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92: 549-555
4. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122: 1101-1112
5. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N (1999) Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 94: 86-91
6. Clayton D, Schifflers E (1987a) Models for temporal variation in cancer rates. I: age-period and age-cohort models. Stat Med 6: 449-467
7. Clayton D, Schifflers E (1987b) Models for temporal variation in cancer rates. II: age-period-cohort models. Stat Med 6: 469-481
8. Corley DA, Buffler PA (2001) Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in five Continents database. Int J Epidemiol 30: 1415-1425
9. Driessen A, Van Raemdonck D, De Leyn P, Filez L, Peeters M, Winnepenninckx V, Penninckx F, Lerut T, Ectors N (2003) Are carcinomas of the cardia oesophageal or gastric adenocarcinomas? Eur J Cancer 39: 2487-2494
10. El-Serag HB (2002) The epidemic of esophageal adenocarcinoma. Gastroenterol Clin N Am 31: 421-440, viii
11. El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer JR (2005) Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 100: 2151-2156
12. El-Serag HB, Mason AC, Petersen N, Key CR (2002) Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 50: 368-372
13. Eurocim v. 4.0 (2001) European incidence database V2.3, ICD-10 dictionary (2001). Lyon: European Network of Cancer Registries
14. Gammon MD, Terry MB, Arber N, Chow WH, Risch HA, Vaughan TL, Schoenberg JB, Mayne ST, Stanford JL, Dubrow R, Rotterdam H, West AB, Fraumeni Jr JF, Weinstein IB, Hibshoosh H (2004) Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev 13: 34-39
15. Gulmann C, Rathore O, Grace A, Hegarty H, O'Grady A, Leader M, Patchett S, Kay E (2004) Cardiac-type' (mucinous) mucosa and carditis are both associated with Helicobacter pylori-related gastritis. Eur J Gastroenterol Hepatol 16: 69-74
16. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H (1978) Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 70: 1-5
17. Hampel H, Abraham NS, El-Serag HB (2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143: 199-211
18. Hansen S, Melby KK, Aase S, Jellum E, Vollset SE (1999) Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand J Gastroenterol 34: 353-360
19. Heitmiller RF, Sharma RR (1996) Comparison of prevalence and resection rates in patients with esophageal squamous cell carcinoma and adenocarcinoma. J Thorac Cardiovasc Surg 112: 130-136
20. Helin-Salmivaara A, Klaukka T, Huupponen R (2003) Heavy users of nonsteroidal anti-inflammatory drugs: a nationwide prescription database study in Finland. Eur J Clin Pharmacol 59: 477-482
21. Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G (2002) Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 123: 60-67
22. Lagergren J, Bergstrom R, Lindgren A, Nyren O (2000) The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 85: 340-346
23. Laheij RJ, Straatman H, Verbeek AL, Jansen JB (1999) Mortality trend from cancer of the gastric cardia in The Netherlands, 1969-1994. Int J Epidemiol 28: 391-395
24. McColl KE (2005) When saliva meets acid: chemical warfare at the oesophagogastric junction. Gut 54: 1-3
25. McColl KE (2006) Cancer of the gastric cardia. Best Pract Res Clin Gastroenterol 20: 687-696
26. Morson BC, Belcher JR (1952) Adenocarcinoma of the esophagus and ectopic gastric mucosa. Br J Cancer 6: 127
27. Naef AP, Savary M, Ozzello L (1975) Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 70: 826-835
28. Richter JE, Falk GW, Vaezi MF (1998) Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol 93: 1800-1802
29. Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meuwissen SG, van Kamp GJ, Vandenbroucke-Grauls CM (1997) Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 92: 1480-1482
30. Schnitzer TJ, Kong SX, Mavros PP, Straus WL, Watson DJ (2001) Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. Clin Ther 23: 1984-1998
31. Siersema PD, Verschuur EM, Homs MY, van der Gaast A, Eijkenboom WM, Kuipers EJ (2005) [Palliative treatment in patients with oesophagus carcinoma]. Ned Tijdschr Geneeskd 149: 2775-2782
32. Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85: 1457-1459
33. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60: 5767-5772
34. Souza RF, Spechler SJ (2005) Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 55: 334-351
35. Spechler SJ (2002) Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. Gastroenterology 122: 1518-1520
36. Suzuki H, Iijima K, Scobie G, Fyfe V, McColl KE (2005) Nitrate and nitrosative chemistry within Barrett's oesophagus during acid reflux. Gut 54: 1527-1535
37. Tsibouris P, Hendrickse MT, Isaacs PE (2004) Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther 20: 645-655
38. van Blankenstein M, Bohmer CJ, Hop WC (2004) The incidence of adenocarcinoma in Barrett's esophagus in an institutionalized population. Eur J Gastroenterol Hepatol 16: 903-909
39. van Blankenstein M, Hop WCJ, Looman CWN, Bytzer P (2005) The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett's esophagus makes a difference. Am J Gastroenterol 100: 766-774
40. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ (2005) Increasing incidence of Barrett's oesophagus in the general population. Gut 54: 1062-1066
41. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6: 945-952
42. Visscher TL, Kromhout D, Seidell JC (2002) Long-term and recent time trends in the prevalence of obesity among Dutch men and women. Int J Obes Relat Metab Disord 26: 1218-1224
43. Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW (1999) Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg 86: 529-535
44. Wu AH, Crabtree JE, Bernstein L, Hawtin P, Cockburn M, Tseng CC, Forman D (2003) Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 103: 815-821